top of page
happy couple red psd.jpg

Pipeline

Disease

Program

Pre-Clinical

Phase 1

Phase 2

Phase 3

seyltx gradient arrow.png

Ifenprodil

Lead candidate

seyltx gradient arrow.png

NP10679

NCE GluN2B antagonist with optimized PK and target selectivity

Follow-On GluN2B Antagonist

Portfolio of 7 additional novel GluN2B antagonist

seyltx gradient arrow.png

Ifenprodil Prodrug

Optimized PK, absorption, and dosing interval

seyltx gradient arrow.png

Combination Therapy

GluN2B (central) + P2X3 (peripheral) antitussive

seyltx gradient arrow.png
SEYLTX pipeline-03.png
bottom of page